Submitted to=

Submitted by=

DATE OF SUBMISSION: 20 January,2012.

Dr.A.F.M.Aowrangazab

Associate ProfessorDepartment of Management Studies,

Faculty of Business Administration,

University of Chittagong.

Pinkey Chowdhury

(IM/15270)

Nilufar Sharmin

(IM/15262)

Jobayda Akther

(HRM/152

Shirin Akther

(IM/15261)

MBA

Department of Management Studies,

Faculty of Business Administration,

University of Chittagong.

SL NO. Contents Page

1

2

3

4

5

6

7

8

9

10

Company Profile of GlaxoSmithKline

GSK is a global organisation with offices in over 100 countries and major research centres in the UK, USA, Belgium and China. It is listed on the London and New York Stock Exchanges and corporate head office is in Brentford, UK. A research-based pharmaceutical company, GSK has a share of around 5% of the world's pharmaceutical market. It employs 96,500 people with Around 13,000 people working in their research teams to discover new medicines.

Chief Executive Officer: J.P.GarnierChief Financial Officer: John CombeR&D Chairman: Tachi Yamada

Also known as: GSK, Glaxo

Employees: 108,000

Headquarters: London, England 

Other locations: Philadelphia, United StatesResearch Triangle Park, United StatesPresence in 28 other countries

Main Business Activity: Prescription Medication

Other activities: Consumer Healthcare

Analyst Review: GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.

Contact Information

Address: 980 Great West Rd., BrentfordLondon TW8 9GS, United Kingdom

Phone: +44-20-8047-5000

Fax:

Financial Highlights

Fiscal Year End: December

Revenue (2010): 43916.70 M

Revenue Growth (1 yr): (-2.80%)

Employees (2010): 96,500

Employee Growth (1 yr): (-3.40%)

Key People

• Chairman: Sir Christopher Charles (Chris) Gent

• CEO and Director: Andrew Witty

• SVP Global Communications: Philip (Phil) Thomson

Industry Information

Sector: Healthcare

Industry: Drug Manufacturers - Major

Top Competitors

• Novartis AG (nvs)

• Pfizer Inc. (pfe)

• Sanofi (sny)

History of GlaxoSmithKline

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatalogicals and vaccines. The Company’s segments include Pharmaceuticals and Consumer Healthcare. On January 30, 2009, GSK acquired Bristol Myers Squibb Pakistan (Private) Limited. On March 31, 2009, it acquired from UCB S.A. On April 21, 2009, the Company acquired AZ Tika, a wholly owned subsidiary of Astra Zeneca plc. On July 22, 2009, the Company acquired Stiefel Laboratories, Inc. On October 30, 2009, GSK acquired Pfizer Inc.’s HIV business and combined it with its own HIV business to form ViiV Healthcare Limited. On November 10, 2009, GSK acquired the Algerian pharmaceutical, manufacturing and distribution group, Laboratoire Pharmaceutique Algerien. On December 18, 2009, GSK acquired NovaMin Technology Inc. In June 2010, the Company acquired Laboratorios Phoenix S.A.C.yF. In February 2011, the Company sold its entire holding in Quest Diagnostics Inc.

Biopharmaceuticals: Business profileMission:GSK’s mission is to enable GSK and its customers to launch, supply and manage Biopharmaceutical products around the world.We will use our experience and capabilities to deliver a diverse portfolio of biopharmaceutical products, maximizing value for GSK and its customers.

Full service provider

Our leading edge manufacturing facilities are designed for preparation and fill/finish of bulk biopharmaceutical products derived from mammalian, insect, and microbial cells.The key elements of the facility are: Independent Cell Culture and Microbial Suites –mammalian and insect cell culture capacity

at 10,000 litre (2x5,000L bioreactors) and microbial capacity at 20,000 litre (2 x 10,000L bioreactors)

Independent Product Purification Suites - providing complete segregation of products Flexible clean room capacity Advanced monitoring and control of processes Testing Laboratories with a full array of testing capabilities and development - Microbial,

Biological and Chemical cGMP Compliant Warehousing - for cell banks, raw materials and formulated bulk product Extensive Cold Storage Facilities Sample storage - including stability samples

Fill/Finish Capability QC analytical/release testing in the US and EU

Manufacturing solutions

We provide all the advantages you need for a successful contract manufacturing partnership: Cost-effective commercial investment Considerable corporate resources Cost-effective operational scale Rapid development of products Highly experienced professionals Leading-edge facilities Tradition of innovation Proven operational excellence

Biopharm successes

Proven track record of multiple successful technology transfers of both clinical and commercial products internally and externally

FDA multi-product licensed facilities Proficient in supporting numerous biopharmaceutical technology platformsBusiness strategy

Figure 1 Core pharmaceutical R & D

Geographic Presence

GSK is present in more than 100 countries across the World. The major geographical division of GSK is US , Europe,Asia pacific/Japan and Emerging Market.

Product Portfolio

Respiratory

Seretide/Advair, a combination of Serevent and Flixotide, offers a long-acting bronchodilator and an anti-inflammatory in a single inhaler. It is approved for the treatment of asthma and COPD.

Flixotide/Flovent and Beclovent are inhaled steroids for the treatment of inflammation associated with asthma and COPD.

Serevent is a long-acting bronchodilator used to treat asthma and COPD, and Ventolin is a selective short-acting bronchodilator used to treat bronchospasm.

Veramyst/Avamys, Flixonase/Flonase and Beconase are intra-nasal preparations for the treatment of perennial and seasonal rhinitis.

Central nervous system (CNS)

Seroxat/Paxil is a selective serotonin re-uptake inhibitor (SSRI) for the treatment of major depressive disorder, panic, obsessive compulsive disorder, post traumatic stress disorder, social anxiety disorder, premenstrual dysphoric disorder, and general anxiety disorder. A controlled release forumulation, Paxil CR, is available in the USA.

Wellbutrin is an anti-depressant, available in the USA and many European and international markets in normal, sustained-release (SR) and once daily (XL) formulations.

Imigran/Imitrex is a 5HT1 receptor agonist used for the treatment of severe or frequent migraine and cluster headache, and has become the reference product in this sector. Naramig/Amerge is also a 5HT1 receptor agonist indicated for the treatment of migraine.

Lamictal, a well established treatment for epilepsy, is also indicated for bipolar disorder.

Requip is a specific dopamine D2/D3 receptor agonist indicated for the treatment of Parkinson's disease and Restless Legs Syndrome (RLS).

Anti-virals

In November 2009, GSK's HIV/AIDS medicines became the property of ViiV Healthcare.

Zeffix has been approved for marketing in the USA, Europe, China and other markets for the treatment of chronic hepatitis B.

Valtrex is a treatment for episodic genital herpes as well as the long term suppression and reduction of transmission of genital herpes, zoster (shingles), cold sores and chicken pox. Valtrex supersedes Zovirax , which is also used to treat herpes infections.

Relenza is an anti-viral used to prevent and treat influenza.

Anti-bacterials

Augmentin is a broad-spectrum antibiotic suitable for the treatment of a wide range of common bacterial infections and is particularly effective against respiratory tract infections. Augmentin ES-600 is an extra strength suspension specifically designed to treat children with recurrent or persistent middle ear infections.

Augmentin XR is an extended release formulation for the treatment of patients with community acquired pneumonia or acute bacterial sinusitis.

Altabax/Altargo, approved in 2007 for the topical treatment of certain bacterial skin infections, represents the first new class of topical antibiotics approved by the FDA in nearly two decades.

Ceftin/Zinnat is an oral antibiotic used primarily for community acquired infections of the lower respiratory tract.

Metabolic

Avandia is a potent insulin sensitising agent which acts on the underlying pathophysiology of type 2 diabetes. For more information about Avandia and associated products, visit the Avandia section of this website.

Bonviva/Boniva is a long acting bisphosphonate available in once-monthly oral and quarterly injection forms for the treatment of osteoporosis (co-promoted with Roche)

Vaccines

GlaxoSmithKline markets over 30 vaccines worldwide, of which more than half are combination vaccines to protect children, adolescents and/or adults against up to six diseases at the same time.

Cervarix is a vaccine intended to protect females against the diseases caused by infection with Human Papillomavirus (HPV) types 16 and 18. These diseases include cervical cancer and precancerous cervical lesions.

Infanrix is a range of paediatric vaccine combinations. Infanrix provides protection against diphtheria, tetanus and pertussis (whooping cough). Infanrix penta (Europe) / Pediarix (USA and Canada) provides additional protection against hepatitis B and polio, and Infanrix hexa further adds protection against Haemophilus influenzae type b, which causes meningitis. Boostrix is available to add protection against pertussis (whooping cough) to the routine tetanus/diphtheria booster administered to teenagers.

In GSK's hepatitus range, Havrix protects against hepatitis A and Engerix-B against hepatitis B.

Twinrix is the only available combined hepatitis A and B vaccine, protecting against both diseases with one vaccine and available in both adult and paediatric strengths. In Europe, FENDrix, a vaccine to prevent hepatitis B in patients with renal insufficiency including high-risk groups such as pre-haemodialysis and haemodialysis patients, is available from 15 years of age onwards.

GSK added Fluviral to its portfolio of products when it acquired the Canadian vaccine manufacturer ID Biomedical Corporation in December 2005. Fluviral is marketed in Canada and, following FDA approval, the USA where it is approved for the active immunisation of adults 18 years and older against infl uenza disease under the brand FluLaval. Fluviral and FluLaval add to Fluarix GSK’s seasonal ‘flu vaccine, which is distributed in 79 countries including the USA.

GSK also markets Priorix, a measles, mumps and rubella vaccine, Typherix, a vaccine for protection against typhoid fever, and Varilrix, a vaccine against varicella or chicken pox. Priorix-Tetra, GSK’s new combination vaccine to prevent measles, mumps, rubella and varicella (MMRV) was first launched in Germany in August 2006.

In addition, the Group markets a range of vaccines to prevent meningitis under the umbrella name Mencevax. GSK’s new Hib- MenC vaccine, Menitorix is now available in the UK. GSK’s meningitis vaccine portfolio will be complemented by new meningitis conjugate vaccines in the near future.

As part of its paediatric franchise, GSK continued to roll out the launch of its vaccine against rotavirus induced gastroenteritis, Rotarix, which is now launched in 90 countries worldwide. Rotavirus vaccination has been included in the national vaccination calendar of fi ve Latin American countries where Rotarix will be available free at public health clinics, as part of governmental paediatric immunisation programmes.

Oncology and emesis

Tykerb is an oral treatment for patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab. Tykerb was approved in the USA in 2007 and is now available in Europe, where is is known as Tyverb.

Hycamtin is a second line treatment for ovarian, cervical and small cell lung cancer.

Bexxar is a treatment for patients with CD20 follicular, non-Hodgkin’s lymphoma with and without transformation whose disease is refractory to rituximab and who have relapsed following chemotherapy.

Arranon (nelarabine) a treatment for patients with T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma.

Zofran is used to prevent nausea and vomiting associated with chemotherapy and radiotherapy for cancer, and is available in both oral and injectable forms. It is also approved for use in the prevention and treatment of post-operative nausea and vomiting.

Cardiovascular and urogenital

Coreg is an alpha/beta blocker which has been proven to be effective in treating patients with mild, moderate and severe heart failure, heart attack or hypertension. GSK has sole marketing rights in the USA and Canada. A controlled release formulation, Coreg CR is also available in the USA. Generic versions of Coreg are available in the USA and Canada.

Levitra is a PDE-5 inhibitor indicated for male erectile dysfunction. GSK has co-promotion rights in the USA and more than 20 other markets.

Avodart is a 5-ARI inhibitor currently indicated for benign prostatic hyperplasia. A large clinical study is underway examining its efficacy in reducing the risk of prostate cancer.

Vesicare is an anti-muscarinic indicated for overactive bladder. GSK has co-promotion rights with Astellas in the USA. Its major competitors are Detrol LA, Ditropan XL/generic oxybutynin, and Enablex.

Arixtra, a selective Factor Xa inhibitor, is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of DVT and PE in patients undergoing major orthopaedic surgery, abdominal surgery and acutely ill medical patients (EU only). Also in the EU, Arixtra is indicated for the treatment of patients with acute coronary (unstable angina, NSTEMI and STEMI).

Fraxiparine is a low-molecular weight heparin indicated for prophylaxis of thromboembolic disorders (particularly deep vein thrombosis and pulmonary embolism) in general surgery and in

orthopedic surgery, treatment of deep vein thrombosis and prevention of clotting during haemodialysis.

Integrilin is a GP IIb-IIIa inhibitor, approved in the EU for the prevention of early myocardial infarction in patients with unstable angina or non-Q-wave MI.

Dermatologicals

The dermatology portfolio includes heritage GSK products (e.g. Bacroban, Duac and Zovirax) and those acquired through business acquisitions, principally Stiefel in July 2009.

Other

This category includes Betnovate, the higher potency Dermovate and the newer Cutivate, which are anti-inflammatory steroid products used to treat skin diseases such as eczema and psoriasis, Relafen, a non-steroidal anti-inflammatory drug for the treatment of arthritis, and Zantac, for the treatment of peptic ulcer disease and a range of gastric acid related disorders.

Employee Distribution

Figure:Employee distribution

Business Summary

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, HIV, central nervous system, anti-bacterials, metabolic, vaccines, oncology and emesis, cardiovascular and urogenital, and dermatologicals. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 30 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company provides OTC medicines, including Panadol, a paracetamol-based treatment of headache and joint pain, fever, and cold symptoms; Gaviscon, a range of antacid products that relieve heartburn due to acid reflux; alli, a weight loss product; and NicoDerm, NiQuitin CQ, Nicabate, and Nicorette for the treatment of nicotine withdrawal as an aid to quit smoking. Further, it offers oral healthcare products comprising Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes for the prevention of dental sensitivity; Biotene, a mouthwash and gel to treat dry mouth; and Polident, Poligrip, and Corega, which are denture adhesives and cleansers. Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks for energy and hydration; Horlicks, a malted, milk-based drink and food for nutrition application; and Ribena, a blackcurrant juice-based drink, as well as markets skincare products. GlaxoSmithKline plc was founded in 1999 and is headquartered in Brentford, United Kingdom.

Products of GlaxoSmithKline

Pharmaceutical products

GSK’s principal pharmaceutical products are directed to nine therapeutic areas, including dermatologicals, respiratory, central nervous system, anti-virals, metabolic, vaccines, cardiovascular and urogenital, anti-bacterials, and oncology and emesis. Its products for respiratory therapeutic area include Seretide/Advair, Flixotide/Flovent, Serevent, Veramyst and Flixonase/Flonase. Its products for anti-virals include Epzicom/Kivexa, Combivir, Trizivir, Agenerase, Lexiva, Epivir, Ziagen, Valtrex, Zeffix and Relenza. The products for central nervous system include Lamictal, Imigran/lmitrex, Seroxat/Paxil, Wellbutrin SR, Requip and Treximet. The Company’s products for cardiovascular and urogenital areas include Avodart, Lovaza, Coreg CR, Fraxiparine, Arixtra and Vesicare. Its Metabolic products include Avandia and Avandamet. Anti-bacterials include products, such as Augmentin and Altabax. Oncology and emesis products include Arzerra, Hycamtin, Promacta/Revolade, Tykerb/Tyverb and Votrient.

The Company’s products for vaccines include Infanrix/Pediarix, Fluarix, FluLaval, Cervarix, Synflorix and Rotarix.

The Company competes with Abbott Laboratories, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche Holdings and Sanofi-Aventis.

Consumer Healthcare products

GSK’s portfolio of consumer healthcare products consists of three categories: OTC medicines, oral healthcare and nutritional healthcare. The OTC medicines include alli, a weight loss medicine to be available without a prescription; Panadol, a paracetamol/acetaminophen analgesic; NicoDerm, NiQuitin CQ, Nicabate and in the United States Nicorette, smoking control products, and other brands, including Breathe Right nasal strips, Tums, Citrucel, Contac and FiberChoice. Oral healthcare products include Aquafresh, a range of toothpastes, toothbrushes and mouthwashes; Sensodyne, a range of toothpastes, toothbrushes and mouthwashes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; Polident, PoliGrip and Corega, the denture care cleansers and adhesives, and other brands, such as Odol, Macleans and Dr Best. Nutritional healthcare products include Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks, and Ribena, a blackcurrant juice-based drink.The Company competes with Colgate-Palmolive, Johnson & Johnson, Procter & Gamble, Unilever and Pfizer.

Market Overview

Figure 2 VACCINE sales in different countries

Market Share

GSK Merck Sanofi Pfizer Novartis

DTPw combos Y Y Y

DTPa combos Y Y

MMR Y Y Y

HEP a Y Y Y

Rotavirus Y Y

Meningococcal Y Y D

Influenza Y Y Y

Pneumococcal Y Y

HPV Y Y

Malaria D

Dengue D D

D= In Developement

Clinical Trial

Pediatric Vaccine

Vaccine Indication Phase

Heptavalent combination vacine

Neisseriamenhibrix meningitis C , haemophilus Influenza type b, Diptheria, HepB, Tetanus, pertussis and poliomyelitis disease prophylaxis

II

MMR Measeles mumps rebella propylaxis II(US)

S.Pneumoniae pediatric next generation

Streptococcus pneumoniae disease prophylaxis II

Mosquirix Malaria prophylaxis III

Nimenrix Neisseria meningtis groups A,C,W,Y Submited

Menhibrix Neisseria meningtis group C & Y & haemophilus Influenza type b Submited

Other Vaccine

Vaccine Indication Phase

Flu Pandemic Pandemic influenza prophylaxis I

HIV HIV prophylaxis I

HIV HIV immunotherapy II

Tb TB prophylaxis II

Flu Vaccine Seasonal influenza prophylaxis III

Zoster Herpes Zoster prevention III

Flu (pre-) Pandemic

Pre pandemic and pandemic influenza prophylaxis

Submitted

Pumariz Pandemic Influeza Prophylaxis Submitted

SWOT analysis of GSK

History of GlaxoSmithKline Bangladesh

About GlaxoSmithline(GSK)Bangladesh Limited carries with it an enviable image and reputation for the past 6 decades. A subcidiary of GlaxoSmithcline PLC-one of the worlds leading research- based pharmaceutical and healthcare companies GSK Bangladesh,continoues to be committed to improving the quality of human life by enabling people to do more,feel better and live longer.The companies principle activities include secondary manufacture of phamacerutical products and marketing of vaccines,pharmaceutical healthcare products and health food drinks.

In 1949 The company committed its journey In Bangladesh with its corporate identity as Glaxo in Chittagong as a importer of products from Glaxo Group companies. It started spreading its spectrum from being an importer to a manufacturer by establishing its own manufacturing unit in Chittagong in1967.The facility till date is considered as one of the centers of Excellence in Global manufacturing and supply network of the Group.

The global corporate mergers and acquisitions has seen the evolution of the companies identity in the past 6 decades.In line with mergers and acquisitions the identity changed from Glaxo to Glaxo welcome Bangladesh Limited during 2002 After mergers with SmithklineBeecham in December 2000.The mega merger of the company enables it to deliver cutting edge advancement in healthcare solutions.The relentless commitment,setting of standard of ethical standards and quality backed leading edge technology of the company has built in a strong relationship between stakeholders and GSK Bangladesh.With the ever committed 615 numbers of personnel all over the country GSK Bangladesh,Which now comprises of boyh pharma and Consumer,Continually strive to meet the GlaxoSmithKline mission to improve the quality of human life by ensuring healthcare products ,healthdrinks and different corporate social responsibility programs.

GSK is committed to developing new and effective healthcare solutions.The values on which the group was founded have always inspired growth and will continue to do so in times to come.

GSK Bangladesh – A Flashblack

1948(March):

Glaxo Laboratories (Pakistan)Limited was incorporated having its registered office in Karachi.Initially it was a wholly owned subsidiary Of Glaxo Group Limited.

1949(January):

First branch in East Pakistan was opened at Dewnhat,Chittagong.The company was absolutely depended on Imprts from U.K.Mode of delivery products were mainly railway parcel .

1953:

Public offer of shares was made of the request of Govt.As a result Glaxo Group’s shareholding reduced to 70%.

1955:

Karachi factory started production of medicines having sufficient capacity to cover market needs of both East and West Pakistan.

1956:

Second branch in East Pakistan was opened at Motijheel, Dhaka.

1960-1969:

Permission for establishment of a factory at Chittagong was obtained from the Govt. land for Fauzderhat factory was purchased. Plan for factory building at Fauzderhat was passed by Chittagong Divisional Commissioner in 1962.In 1966,Third branch was opened in Khan Jahan Ali Road ,Khulna.East Pakistan head office was established headed by One resident Director.In1967 Chittagong factory went into production. Permission for packing of 1800 tons baby food and 900 tons Glaxose –D was granted by Govt.

1970-1979:

In 1970,packing of Glaxose-D started. All establishment of Glaxo laboratories (Pakistan)Ltd. In the then East Pakistan was vested in the abandoned properties of the Government. In 1973,Realeased from abandoned properties and permission was given by the Government to form a company in Bangladesh. Packing of milk food commenced.Glaxo Bangladesh Limited was incorporated and the first depot was opened at Bogra.Depots at Barisal,Mymensingh and Sylhet was opened.

1980-1989:

In 1980,sales depots at Comilla,Pabna,Narayanganj and Rangpur were opened.To comply with the requirements of Drugs Control Ordinance the company has to discontinue production of all vitamin preparations(Tablet,Syrap,and Injections)and some other products declared as non essential items.Effect on sales was about 25%.Excise duty on medicine was imposed by the Government.In 1983,Sales depots at Rajshahi,Tangai,Faridpur and Dinajpur was opened. The company discontinued packing of baby food. Company’s registered was relocated in Dhaka.

1990-1999:

Company properties at Paribag and Gulshan Dhaka was sold and Registered office relocated at Chittagong.In1995,Renamed as Glaxo Welcome Bangladesh Limited following the BURROUGHS welcome acquisition.

2000-2009:

In 2002, Following the global mega merger with SmithKlineBeechham Identity Changed to GlaxoSmithKline Bangladesh Limited.

Factory of GlaxoSmithKline Bangladesh

The factory produces secondary dosage forms including antibiotics and caters Toll manufacturing to a limited extent.The eight different departments comprising GSM Chittagong are Human Resource(HR)s,Production(PROD),Quality assurance(QA),Engineering(ENG),Planning and Supply(P & S),Environment ,Health and Safety(EHS),Procurement(PROC),Finance and Information Technology(IT).

GSM Chittagong has sustainability performed well in past Quality and Safety audits throughout the years and has increasingly showed the trend of building the capacity in terms of quality, productivity and work environment. The site has recently brought in a number of production machineries to bring its manufacturing excellence to the fullest. The notion would continue in upcoming years and gradually the focus will be shifted towards developing a sustainable performance culture to a truly slow cost solution.GSM Chittagong is a tobacco free site. “QMS place, in use”-logo embedded on outside building wall of the factory demonstrates how seriously the factory nourishes the concept of Quality in its operations.GSM Chittagong employs around 400 direct and indirect employees of which 21% are female. Till date there 2 GSK certified auditors ,1 QMS Champion and 1 QE champion and 10 green belts.

Products of GSK Bangladesh

GSK Bangladesh’s portfolio includes both pharmaceutical products and consumer products.

Social corporate Responsibilities of GSK Bangladesh

Following their mission statement at present they are working towards making the privileged people’s life better by working with local partners in providing education, infrastructure and health. They also remain to be responsible to the society in which they operate by standing beside them in their need specially during natural calamities, disaster management which includes extending help during floods,cyclones,rehabilitation following fire, earthquakes etc.Amongst some of GSK Bangladesh’s projects are the:Village transformation project,the PHASE project,The free primary school project,Lymphatic Filirisis project etc.

Recommendation

With respect to GSK , Serum can go in for the following options:

Low cost Manufacturing Strategic Partnership for marketing of Serum Products

Reference:

1.http://www.gsk.com.bd/

2.